Hodifa Yara, Khalayli Naram, Hodaifa Amr, Kudsi Maysoun
Faculty of Medicine, Damascus University.
Rheumatology, Faculty of Medicine, Damascus University, Damascus, Syria Arab Republic.
Ann Med Surg (Lond). 2023 Jun 20;85(8):4118-4120. doi: 10.1097/MS9.0000000000001015. eCollection 2023 Aug.
Coronavirus disease 19 (COVID-19) has become the most serious public health crisis of our generation, and vaccines are effective in preventing its infection. Remitting seronegative symmetrical synovitis with pitting edema is an idiopathic rare benign syndrome, but it could be secondary to aautoimmune diseases. Here, the authors reported the first case of this syndrome's development after COVID-19 vaccination.
A 52-year-old woman presented with hand edema, arthralgia, and morning stiffness, after receiving the second dose of m RNA COVID-19 vaccination. Examination revealed edema in the dorsum of both hands and symmetrical tenderness of the shoulders, elbows, wrists, knees, and ankles. Blood test results were normal except for elevated levels of C-reactive protein. The immune profile and the tuberculin test were also negative. A hand radiograph showed soft tissue edema. Ultrasonography of the extremities has shown tenosynovitis. Remitting seronegative symmetrical synovitis with pitting edema syndrome was diagnosed according to the diagnostic criteria. She was treated with 30 mg/day prednisolone, with a complete disappearance of edema and arthralgia after 10 days, and the C-reactive protein level was decreased.
Vaccines are still the most effective and protective method against COVID-19 infection, but it may trigger an immunological response. Remitting seronegative symmetrical synovitis with pitting edema (or sometimes RS 3 PE) is a rare nonunderstood syndrome identified by symmetric polyarthritis, synovitis, acute pitting edema of hands and/or feet, and a negative serum rheumatoid factor, with an excellent prognosis to treatment with steroid. Usually occurred in the old aged population, young patients' cases were mentioned. As the authors did not find any data about our subject, this is the first case of this syndrome development after the second dose of COVID-19 vaccination.
The occurrence of acute symmetrical seronegative polysynovitis with extremities edema, in the elderly, should guide toward the diagnosis of this syndrome.
新型冠状病毒肺炎(COVID-19)已成为我们这一代人最严重的公共卫生危机,而疫苗在预防其感染方面是有效的。缓解性血清阴性对称性滑膜炎伴凹陷性水肿是一种特发性罕见良性综合征,但也可能继发于自身免疫性疾病。在此,作者报告了首例在接种COVID-19疫苗后出现该综合征的病例。
一名52岁女性在接种第二剂mRNA COVID-19疫苗后出现手部水肿、关节痛和晨僵。检查发现双手背部水肿,双肩、双肘、双腕、双膝和双踝对称性压痛。除C反应蛋白水平升高外,血液检查结果正常。免疫指标和结核菌素试验也均为阴性。手部X线片显示软组织水肿。四肢超声检查显示腱鞘炎。根据诊断标准诊断为缓解性血清阴性对称性滑膜炎伴凹陷性水肿综合征。她接受了每日30毫克泼尼松龙治疗,10天后水肿和关节痛完全消失,C反应蛋白水平下降。
疫苗仍然是预防COVID-19感染最有效和最具保护性的方法,但它可能引发免疫反应。缓解性血清阴性对称性滑膜炎伴凹陷性水肿(或有时为RS 3 PE)是一种罕见的、尚未完全了解的综合征,其特征为对称性多关节炎、滑膜炎、手足急性凹陷性水肿以及血清类风湿因子阴性,对类固醇治疗预后良好。通常发生在老年人群中,也有年轻患者的病例报道。由于作者未找到关于本病例的任何数据,这是首例在接种第二剂COVID-19疫苗后出现该综合征的病例。
老年人出现急性对称性血清阴性多滑膜炎伴肢体水肿,应考虑诊断为本综合征。